Bryan P Schneider

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. ncbi request reprint Triple-negative breast cancer: risk factors to potential targets
    Bryan P Schneider
    Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, USA
    Clin Cancer Res 14:8010-8. 2008
  2. pmc Potential roles of microRNAs in regulating long intergenic noncoding RNAs
    Liran Juan
    Center for Biomedical Informatics, Harbin Institute of Technology School of Computer Science and Technology, Harbin, Heilongjiang 150001, China
    BMC Med Genomics 6:S7. 2013
  3. pmc Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial
    Bryan P Schneider
    Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 19:1281-9. 2013
  4. pmc Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
    Bryan P Schneider
    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Lancet Oncol 13:e427-36. 2012
  5. pmc Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer
    Bryan P Schneider
    Eastern Cooperative Oncology Group, 535 Barnhill Dr, Indiana Cancer Pavilion, Indianapolis, IN 46202, USA
    J Clin Oncol 30:3051-7. 2012
  6. pmc A large, consistent plasma proteomics data set from prospectively collected breast cancer patient and healthy volunteer samples
    Catherine P Riley
    Bindley Bioscience Center, Purdue University, West Lafayette, IN, USA
    J Transl Med 9:80. 2011
  7. pmc Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?
    Bryan P Schneider
    Indiana University Simon Cancer Center, Indianapolis, IN 46220, USA
    Breast Cancer Res 11:303. 2009
  8. pmc Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
    Bryan P Schneider
    Indiana University School of Medicine, Indianapolis, IN, USA
    J Clin Oncol 26:4672-8. 2008
  9. doi request reprint Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes
    Bryan P Schneider
    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    Breast Cancer Res Treat 116:543-9. 2009
  10. ncbi request reprint Association of polymorphisms of angiogenesis genes with breast cancer
    Bryan P Schneider
    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    Breast Cancer Res Treat 111:157-63. 2008

Detail Information

Publications22

  1. ncbi request reprint Triple-negative breast cancer: risk factors to potential targets
    Bryan P Schneider
    Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, USA
    Clin Cancer Res 14:8010-8. 2008
    ..This CCR focus article will review the current state of the art on triple-negative breast cancer...
  2. pmc Potential roles of microRNAs in regulating long intergenic noncoding RNAs
    Liran Juan
    Center for Biomedical Informatics, Harbin Institute of Technology School of Computer Science and Technology, Harbin, Heilongjiang 150001, China
    BMC Med Genomics 6:S7. 2013
    ..Despite these advances, the comprehensive miRNA regulation pattern of lincRNA has not been clarified...
  3. pmc Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial
    Bryan P Schneider
    Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 19:1281-9. 2013
    ..We have previously reported associations between candidate VEGFA single-nucleotide polymorphisms (SNP) and overall survival (OS) in E2100. The associations between tumor VEGFA amplification and outcome are evaluated here...
  4. pmc Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
    Bryan P Schneider
    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Lancet Oncol 13:e427-36. 2012
    ..In this Review we provide an overview of available data with particular attention paid to the pitfalls and strengths of potential biomarkers. We also highlight continuing work and plans for confirmatory studies...
  5. pmc Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer
    Bryan P Schneider
    Eastern Cooperative Oncology Group, 535 Barnhill Dr, Indiana Cancer Pavilion, Indianapolis, IN 46202, USA
    J Clin Oncol 30:3051-7. 2012
    ..Therefore, we sought to determine whether neuropathy was associated with breast cancer recurrence in a clinical trial population who received adjuvant taxane therapy...
  6. pmc A large, consistent plasma proteomics data set from prospectively collected breast cancer patient and healthy volunteer samples
    Catherine P Riley
    Bindley Bioscience Center, Purdue University, West Lafayette, IN, USA
    J Transl Med 9:80. 2011
    ..Variability of plasma sample collection and of proteomics technology platforms has been detrimental to generation of large proteomic profile datasets from human biospecimens...
  7. pmc Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?
    Bryan P Schneider
    Indiana University Simon Cancer Center, Indianapolis, IN 46220, USA
    Breast Cancer Res 11:303. 2009
    ..How concerning are these preclinical studies, and should they affect our willingness to explore anti-VEGF therapy in the adjuvant setting?..
  8. pmc Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
    Bryan P Schneider
    Indiana University School of Medicine, Indianapolis, IN, USA
    J Clin Oncol 26:4672-8. 2008
    ..Therefore, we evaluated the association of VEGF genotype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as initial chemotherapy for metastatic breast cancer...
  9. doi request reprint Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes
    Bryan P Schneider
    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    Breast Cancer Res Treat 116:543-9. 2009
    ..We evaluated the association between germline polymorphisms in genes important to angiogenesis and subjective reporting of hot flashes...
  10. ncbi request reprint Association of polymorphisms of angiogenesis genes with breast cancer
    Bryan P Schneider
    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    Breast Cancer Res Treat 111:157-63. 2008
    ..We report our preliminary data evaluating the association of polymorphisms from seven genes known to influence angiogenesis with the likelihood of having breast cancer...
  11. ncbi request reprint Angiogenesis of breast cancer
    Bryan P Schneider
    Division of Hematology Oncology, Indiana University, 535 Barnhill Dr, RT 473 Indianapolis, IN 46202, USA
    J Clin Oncol 23:1782-90. 2005
  12. ncbi request reprint The role of vascular endothelial growth factor genetic variability in cancer
    Bryan P Schneider
    Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, USA
    Clin Cancer Res 15:5297-302. 2009
    ..If validated, these finding could help direct which subgroup of patients should receive bevacizumab...
  13. ncbi request reprint A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors
    Kenneth A Kesler
    Department of Surgery, Cardiothoracic Division, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Ann Thorac Surg 85:371-8. 2008
    ..We reviewed our institution's 25-year experience in the cisplatin era to determine surgical risks and predictors of survival after surgery for PMNSGCT...
  14. ncbi request reprint Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer
    E Gabriela Chiorean
    Department of Medicine, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana Department of Medicine, University of Washington, Seattle, Washington Electronic address
    Int J Radiat Oncol Biol Phys 89:284-91. 2014
    ..To define the safety, efficacy, and pharmacogenetic and pharmacodynamic effects of sorafenib with gemcitabine-based chemoradiotherapy (CRT) in locally advanced pancreatic cancer...
  15. ncbi request reprint Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes
    Bryan P Schneider
    Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
    Breast Cancer Res Treat 96:209-15. 2006
    ..These genes include vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS)...
  16. ncbi request reprint Drug insight: VEGF as a therapeutic target for breast cancer
    Bryan P Schneider
    Indiana University, Division of Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN, USA
    Nat Clin Pract Oncol 4:181-9. 2007
    ..This Review will focus on the current state of therapeutics designed to inhibit this angiogenic process in breast cancer...
  17. doi request reprint Resequencing of the vascular endothelial growth factor promoter reveals haplotype structure and functional diversity
    Milan Radovich
    Department of Medicine, Division of Hematology, Indiana University School of Medicine, Indianapolis, IN, USA
    Angiogenesis 13:211-8. 2010
    ..Haplotypes containing SNPs previously reported to be associated with increased survival with the use of bevacizumab are high-expressing haplotypes, thus lending putative functional evidence to the prior clinical finding...
  18. pmc Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing
    Milan Radovich
    Division of General Surgery, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA
    Breast Cancer Res Treat 143:57-68. 2014
    ..In conclusion, use of microdissected normal ductal epithelium from healthy volunteers enables an optimized approach for studying TNBC and uncovers biological heterogeneity mediated by transcriptional chaos. ..
  19. ncbi request reprint Is the blood-brain barrier relevant in metastatic germ cell tumor?
    Jose M Azar
    Department of Medicine, Division of Hematology and Oncology, Indiana University, Indianapolis, IN, USA
    Int J Radiat Oncol Biol Phys 69:163-6. 2007
    ..We propose to document that the BBB is also relevant in germ cell tumors despite their dramatic chemosensitivity...
  20. doi request reprint Compliance differences between patients with breast cancer in university and county hospitals
    Ian K Komenaka
    Department of Surgery, Indiana University, IN 46202, USA
    Clin Breast Cancer 10:385-91. 2010
    ..Compliance with recommended breast cancer treatments outside the context of a clinical trial differs from that in study populations. The purpose of this study was to examine differences in compliance of breast cancer treatments...
  21. ncbi request reprint Outcome of patients with residual germ cell or non-germ cell malignancy after resection of primary mediastinal nonseminomatous germ cell cancer
    Bryan P Schneider
    Divisions of Hematology Oncology, Indiana Cancer Pavilion, Indianapolis, IN 46202 5289, USA
    J Clin Oncol 22:1195-200. 2004
    ..To identify prognostic variables and outcomes in patients with primary mediastinal nonseminomatous germ cell tumor (PMNSGCT) with postchemotherapy resection of persistent cancer...
  22. ncbi request reprint Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study
    Bryan P Schneider
    Division of Hematology Oncology, Indiana University Medical Center and Walther Cancer Institute, Indianapolis, IN 46202, USA
    Oncology 65:218-23. 2003
    ..To determine the response rate, duration of response and survival with weekly gemcitabine plus docetaxel in metastatic or unresectable pancreatic cancer...